ציין מניה או מטבע קריפטוגרפי בשורת החיפוש כדי לקבל סיכום
CellaVision AB
CEVICellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Proficiency Software, a web-based software designed to help laboratory managers assess, monitor, and promote staff competency in cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. Further, the company offers reagents to identify cell and tissue morphology, parasites, and bacteria in diagnosing various diseases; and instruments, including RAL SmearBox, RAL Stainbox, and RAL Stainer. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden. Address: MobilvAegen 12, Lund, Sweden, 223 62
Analytics
מחיר יעד של וול סטריט
2 773.87 SEKיחס רווח למחיר
40.844תשואת דיבידנד
0.96 %השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
דמויות מפתח CEVI
ניתוח דיבידנדים CEVI
גידול דיבידנד במשך 5 שנים
50 %צמיחה מתמשכת
2 שניםיחס תשלום ממוצע של 5 שנים
35 %היסטוריית דיבידנדים CEVI
שווי מניות CEVI
פיננסיים CEVI
תוצאות | 2019 | דינמיקה |